Your AI-Trained Oncology Knowledge Connection!

Video

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

Author(s):

Rami Komrokji, MD,Andrew Brunner, MD

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
SHAH
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Julie M. Vose, MD, MBA
6369343864112
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Related Content
Raajit K. Rampal, MD, PhD
March 24th 2025

Emerging Therapies in Myelofibrosis Could Extend Beyond JAK Inhibitors

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Physical Functioning Measures With CAR T-Cell Therapy in NHL | Image Credit: © LASZLO– stock.adobe.com
March 23rd 2025

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

R/R DLBCL | Image Credit: © LASZLO - stock.adobe.com
March 20th 2025

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

Image Credit: © Corona Borealis - stock.adobe.com
March 18th 2025

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia